Merck Serono and MorphoSys Enter Strategic Immuno-Oncology Collaboration

13-Jun-2014 - Merck and MorphoSys AG announced that they have signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints. Under the terms of the agreement, MorphoSys and Merck Serono will join forces to develop therapies that modulate the immune system’s natural ...

MorphoSys Strengthens Patent Position on MOR202 Program

25-Jan-2012 - MorphoSys AG announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled ...

MorphoSys and Proteros Biostructures Receive Research Grant

Analysis of Antibody-Antigen-Complex Structures to Allow More Efficient Engineering of Therapeutic Antibodies

13-Oct-2010 - MorphoSys AG and Proteros Biostructures announced that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural ...

MorphoSys Announces Clinical Milestone from Strategic Alliance

Second Clinical Milestone in 2010

05-Jul-2010 - MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. The news represents the second HuCAL-derived antibody to ...

GENEART and MorphoSys Successfully Cooperate in HuCAL PLATINUM Project

19-Dec-2008 - GENEART and MorphoSys announced their successful cooperation in the HuCAL PLATINUM® project. The application of GENEART's proprietary sequence design software GeneOptimizer® and production of significant parts of the antibody library allowed GENEART to make a large contribution to this project, ...

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

28-Nov-2008 - MorphoSys AG and Galapagos NV announced the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. The alliance spans all ...

OncoMed Pharmaceuticals Extends License Agreement for Use of MorphoSys's Core Technology

Parties Initiate First Fully Human Antibody Programs Targeting Cancer Stem Cells

17-Jun-2008 - MorphoSys AG announced that U.S. based biopharmaceutical company OncoMed Pharmaceuticals, Inc. has triggered its pre-existing option to extend the current license agreement between the two companies and has initiated two therapeutic antibody development programs targeting cancer stem cells. ...

Schering-Plough Extends Antibody Alliance with MorphoSys

20-May-2008 - MorphoSys AG announced that Schering-Plough Corporation has decided to extend the current collaboration between the two companies for one year. The collaboration, announced in May 2006, has a maximum term of 5 years until 2011 and may be extended by Schering-Plough after each single year. Under ...

DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Novel Antibody Therapies

27-Mar-2008 - MorphoSys AG announced that DAIICHI SANKYO COMPANY, LIMITED has triggered its pre-existing option to extend the current collaboration between the two companies. The collaboration, originally signed in March 2006, was to end in March 2008. Under the agreement, which is now extended for up to three ...

MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies

26-Feb-2008 - MorphoSys AG announced that Astellas Pharma Inc. has decided to extend the current collaboration between the two companies. The collaboration, originally signed in March 2007, will now run its full term. Under the agreement, which is now extended for four more years until March 2012, Astellas ...